Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs

Executive Summary

With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program

You may also be interested in...



With FDA's REMS Staff Overloaded, Final Guidance Could See Further Delays

The Risk Evaluation and Mitigation Strategy guidance, which has been under construction by FDA for more than a year, could see further delays before it is finalized

With FDA's REMS Staff Overloaded, Final Guidance Could See Further Delays

The Risk Evaluation and Mitigation Strategy guidance, which has been under construction by FDA for more than a year, could see further delays before it is finalized

PhRMA Wants FDA To Explain When Decisions Depart From Committee Votes

FDA should explain the why of its important regulatory decisions in consumer-friendly language, according to the Pharmaceutical Research and Manufacturers of America

Related Content

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel